Subsequent Events	9 Months Ended
Sep. 30, 2014
Subsequent Events	9. Subsequent Events On October 17, 2014, we received written notice from GSK of its election to terminate the product development and commercialization agreement by and between GSK and us dated April 17, 2008, as amended, in light of GSK’s review of its overall research priorities. The effective date of termination will be January 15, 2015 (the “Termination Effective Date”) in accordance with the terms of the agreement, and such termination is irrevocable by GSK. We will not incur any early termination penalties as a result of the termination of the agreement. Upon the Termination Effective Date, all of our research and development obligations and all licenses granted to GSK under the agreement will terminate, and all rights in collaboration targets and compounds will revert to us. Reverse royalties will not be payable by us to GSK. Public Offering In November 2014, we completed an underwritten public offering of 6,088,235 shares of common stock at an offering price of $17.00 per share. This offering included the sale of 4,808,824 shares of common stock by us and 1,279,411 shares of common stock by Isis Pharmaceuticals, Inc. (“Isis”), including the full exercise by the underwriters of their option to purchase additional shares. We received net proceeds from the offering of approximately $76.1 million after deducting underwriting discounts, commissions and other estimated offering expenses payable by us. We did not receive any proceeds from the sale of the shares of common stock by Isis.

9. Subsequent Events

On October 17, 2014, we received written notice from GSK of its election to terminate the product development and commercialization agreement by and between GSK and us dated April 17, 2008, as amended, in light of GSK’s review of its overall research priorities. The effective date of termination will be January 15, 2015 (the “Termination Effective Date”) in accordance with the terms of the agreement, and such termination is irrevocable by GSK. We will not incur any early termination penalties as a result of the termination of the agreement. Upon the Termination Effective Date, all of our research and development obligations and all licenses granted to GSK under the agreement will terminate, and all rights in collaboration targets and compounds will revert to us. Reverse royalties will not be payable by us to GSK.

Public Offering

In November 2014, we completed an underwritten public offering of 6,088,235 shares of common stock at an offering price of $17.00 per share. This offering included the sale of 4,808,824 shares of common stock by us and 1,279,411 shares of common stock by Isis Pharmaceuticals, Inc. (“Isis”), including the full exercise by the underwriters of their option to purchase additional shares. We received net proceeds from the offering of approximately $76.1 million after deducting underwriting discounts, commissions and other estimated offering expenses payable by us. We did not receive any proceeds from the sale of the shares of common stock by Isis.